Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDairy Crest Regulatory News (DCG)

  • There is currently no data for DCG

Trading Statement

31 Jan 2019 07:00

RNS Number : 5883O
Dairy Crest Group PLC
31 January 2019
 

31 January 2019

 

Dairy Crest Group plc ("Dairy Crest")

 

Trading Update

Strong Third Quarter; Full Year In Line With Expectations

 

Dairy Crest is today issuing a Trading Update for the nine months ended 31 December 2018.

 

The company's key brands - Cathedral City, Clover, Country Life and Frylight - all delivered strong volume and revenue growth for the third quarter ended 31 December 2018. On a combined basis, the four brands generated revenue growth of around 10% for the third quarter and 6% for the nine months ended 31 December 2018.

 

In line with our expectations at the time of the Interim Results, Cathedral City had a particularly good third quarter. Both volume and revenue grew by around 10%, helped in part by new product launches, including flavoured snack bars, Lactose Free and a refreshed kids' snacking range.

 

Dairy Crest's spreads brands continue to gain market share. Clover Light with no artificial ingredients was launched in August 2018 and has been voted 'Product of the Year' in the UK spreads category in the world's largest consumer survey for product innovation.

 

Frylight returned to double digit volume and revenue growth in the third quarter, although over the nine month period the brand declined due to the challenging first half of the year.

 

Following a reduction in cream prices, we started to promote Country Life again which led to positive volume and revenue growth in the quarter. The partnership with English Heritage offering 2 for 1 entry began this month.

 

Demand for our functional ingredients - demineralised whey powder and galacto-oligosaccharides (GOS) - continues to increase. In January 2019, daily Promovita GOS 'shots' for consumers went on sale for the first time.

  

There is significant uncertainty around Brexit and the impact of a potentially disorderly exit is hard to predict. Whilst our supply chain and customer base are primarily located in the UK, we are taking steps to reduce our exposure, including accelerating the purchase of ingredients and packaging materials.

 

Notwithstanding this, the outlook for the full year remains in line with our expectations.

 

Mark Allen, Chief Executive of Dairy Crest, commented:

"Our key brands have delivered exceptional performance in the third quarter with all four generating both volume and revenue growth. Demand for our functional ingredients is also increasing, with positive implications for price.

 

"We have launched several major innovations during the past nine months. It is gratifying to have received external validation of one our most technologically advanced achievements, Clover Light with No Artificial Ingredients, by winning 'Product of the Year 2019'. This is the third consecutive year that one of our products has been awarded this accolade."

 

Dairy Crest will issue its Preliminary Results for the year ended 31 March 2019 on23 May 2019.

 

For further information:

Investors/Analysts

 

 

 

Tom Atherton

 

Dairy Crest

01372 472264

Kate Goode

 

Dairy Crest

01372 472236

 

 

 

 

Media

 

 

 

Tim Danaher/Alison Lea

Brunswick

020 7404 5959

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFFRLTIIVIA
Date   Source Headline
2nd Feb 20124:53 pmRNSHolding(s) in Company
2nd Feb 20127:00 amRNSInterim Management Statement
1st Feb 20129:46 amRNSTotal Voting Rights
11th Jan 20125:15 pmRNSDirector/PDMR Shareholding
30th Dec 201110:10 amRNSTotal Voting Rights
30th Nov 20118:54 amRNSTotal Voting Rights
10th Nov 20117:00 amRNSInterim Results Announcement
31st Oct 20118:14 amRNSTotal Voting Rights
14th Oct 20117:00 amRNSDebt refinancing completed
10th Oct 201111:22 amRNSNon Executive Director Appointment
4th Oct 20115:35 pmRNSHolding(s) in Company
4th Oct 20115:33 pmRNSHolding(s) in Company
30th Sep 20118:15 amRNSTotal Voting Rights
19th Sep 20117:00 amRNSTRADING UPDATE
31st Aug 201110:43 amRNSTotal Voting Rights & Capital
8th Aug 20119:29 amRNSAnnual Information Update
2nd Aug 201110:25 amRNSDirector/PDMR Shareholding
2nd Aug 201110:21 amRNSDirector/PDMR Shareholding
1st Aug 20115:21 pmRNSDirector/PDMR Shareholding
29th Jul 20115:07 pmRNSTotal Voting Rights
29th Jul 20115:01 pmRNSDirector/PDMR Shareholding
19th Jul 20116:15 pmRNSResult of AGM
19th Jul 20117:00 amRNSAGM Statement and IMS
30th Jun 201110:10 amRNSTotal Voting Rights
24th Jun 20114:39 pmRNSDirector/PDMR Shareholding
31st May 201110:57 amRNSTotal Voting Rights
31st May 201110:13 amRNSExecutive Director Notification
19th May 20117:00 amRNSFinal Results
12th May 20115:36 pmRNSDirectorate Change
11th May 20119:56 amRNSHolding(s) in Company
11th May 20119:51 amRNSHolding(s) in Company
3rd May 20116:04 pmRNSTotal Voting Rights
1st Apr 20114:46 pmRNSHolding(s) in Company
31st Mar 201111:48 amRNSTotal Voting Rights
31st Mar 20117:00 amRNSTrading statement
28th Feb 201112:37 pmRNSTotal Voting Rights
4th Feb 20117:00 amRNSInterim Management Statement
2nd Feb 201110:01 amRNSHolding(s) in Company
31st Jan 201111:53 amRNSTotal Voting Rights
13th Jan 201112:16 pmRNSDirector/PDMR Shareholding
31st Dec 20109:58 amRNSTotal Voting Rights
1st Dec 201011:26 amRNSDirector/PDMR Shareholding
30th Nov 201012:15 pmRNSTotal Voting Rights
30th Nov 201011:03 amRNSHolding(s) in Company - Amendment
29th Nov 20106:30 pmRNSHolding(s) in Company
11th Nov 20107:00 amRNSHalf Yearly Report
10th Nov 20107:51 amRNSNon-Executive Director Notification
1st Nov 201010:07 amRNSTotal Voting Rights
4th Oct 201012:10 pmRNSNotification of Board change
1st Oct 20109:16 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.